Filing Details

Accession Number:
0000899243-21-019551
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-14 17:20:36
Reporting Period:
2021-05-12
Accepted Time:
2021-05-14 17:20:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1815442 Kymera Therapeutics Inc. KYMR Biological Products, (No Disgnostic Substances) (2836) 812992166
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1821189 Nello Mainolfi C/O Kymera Therapeutics, Inc.
200 Arsenal Yards Blvd., Suite 230
Watertown MA 02472
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-05-12 8,245 $2.08 405,444 No 4 M Direct
Common Stock Disposition 2021-05-12 8,245 $50.05 397,199 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-05-12 8,245 $0.00 8,245 $2.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
216,480 2029-11-13 No 4 M Direct
Footnotes
  1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  3. The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.